Canadian Cancer Trials Group Bulletins


Recent Publication

Canadian Cancer Trials Group REC.2 / ECOG E2805 - ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Sunitinib and sorafenib are used widely in the treatment of renal cell carcinoma (RCC). These agents are associated with a significant incidence of cardiovascular (CV) dysfunction and left ventricular ejection fraction (LVEF) declines, observed largely in the metastatic setting. However, in the adjuvant population, the CV effects of these agents remain unknown.

This publication reports results of a sub-study included in Canadian Cancer Trials Group REC.2 / ECOG E2805 investigating the effects of adjuvant sorafenib and sunitinib on patients' cardiac function. In this sub-study, investigators prospectively defined the incidence of cardiotoxicity among resected, high-risk RCC patients treated with these agents. They found, in the adjuvant setting, a low incidence of cardiotoxicity with sunitinib and sorafenib and conclude these findings may be related to close CV monitoring or potentially to fewer CV comorbidities in this non-metastatic population.

Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res 21: 4048-54, 2015.